NZ518567A - Medicament comprising an inhibitor of 11-beta-hydroxysteroid dehydrogenase in combination with an antigen to induce and/or optimise tolerance induction - Google Patents

Medicament comprising an inhibitor of 11-beta-hydroxysteroid dehydrogenase in combination with an antigen to induce and/or optimise tolerance induction

Info

Publication number
NZ518567A
NZ518567A NZ518567A NZ51856700A NZ518567A NZ 518567 A NZ518567 A NZ 518567A NZ 518567 A NZ518567 A NZ 518567A NZ 51856700 A NZ51856700 A NZ 51856700A NZ 518567 A NZ518567 A NZ 518567A
Authority
NZ
New Zealand
Prior art keywords
antigen
medicament
inhibitor
tolerance
antigens
Prior art date
Application number
NZ518567A
Other languages
English (en)
Inventor
Thomas Wilckens
Original Assignee
Bionetworks Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionetworks Gmbh filed Critical Bionetworks Gmbh
Publication of NZ518567A publication Critical patent/NZ518567A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
NZ518567A 1999-10-28 2000-10-27 Medicament comprising an inhibitor of 11-beta-hydroxysteroid dehydrogenase in combination with an antigen to induce and/or optimise tolerance induction NZ518567A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19951970A DE19951970A1 (de) 1999-10-28 1999-10-28 Arzneimittel für die Toleranzinduktion
PCT/EP2000/010594 WO2001030383A2 (de) 1999-10-28 2000-10-27 Arzneimittel für die toleranzinduktion

Publications (1)

Publication Number Publication Date
NZ518567A true NZ518567A (en) 2004-09-24

Family

ID=7927188

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ518567A NZ518567A (en) 1999-10-28 2000-10-27 Medicament comprising an inhibitor of 11-beta-hydroxysteroid dehydrogenase in combination with an antigen to induce and/or optimise tolerance induction

Country Status (9)

Country Link
EP (1) EP1223974A2 (de)
JP (1) JP2003512438A (de)
KR (1) KR20020057986A (de)
CN (1) CN1391479A (de)
AU (1) AU784245B2 (de)
CA (1) CA2388974A1 (de)
DE (1) DE19951970A1 (de)
NZ (1) NZ518567A (de)
WO (1) WO2001030383A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
US20030198965A1 (en) 2002-04-19 2003-10-23 Isis Pharmaceuticals Inc. Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
CA2516291C (en) * 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20100087413A1 (en) * 2003-09-22 2010-04-08 Thomas Wilckens Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
WO2006059507A1 (ja) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1アンチセンス化合物
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CN107261154A (zh) 2011-04-29 2017-10-20 西莱克塔生物科技公司 致耐受性合成纳米载体
AU2014262163A1 (en) 2013-05-03 2015-11-19 Selecta Biosciences, Inc. Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance
EP3189138A4 (de) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Verfahren und zusammensetzungen zur abschwächung der immunantworten auf antivirale geneditierende transfervektoren
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
JP2019182845A (ja) * 2018-04-02 2019-10-24 学校法人藤田学園 キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
GB8824835D0 (en) * 1988-10-24 1988-11-30 Univ Court Of The University O Administrations of corticosteroids
EP0494224B1 (de) * 1989-09-25 2000-05-10 University Of Utah Research Foundation Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung
JPH04243833A (ja) * 1991-01-28 1992-08-31 Tsumura & Co １１β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤
US5591771A (en) * 1991-12-17 1997-01-07 Michel Fockerman Use of propolis components as an adjuvant
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5883240A (en) * 1995-08-24 1999-03-16 Baker Medical Research Institute Genetic sequences encoding glucocorticoid dehydrogenases and uses therefor

Also Published As

Publication number Publication date
KR20020057986A (ko) 2002-07-12
WO2001030383A2 (de) 2001-05-03
JP2003512438A (ja) 2003-04-02
WO2001030383A3 (de) 2001-11-08
AU784245B2 (en) 2006-02-23
EP1223974A2 (de) 2002-07-24
CA2388974A1 (en) 2001-05-03
DE19951970A1 (de) 2001-05-03
CN1391479A (zh) 2003-01-15
AU1997201A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
AU784245B2 (en) Medicament in order to induce tolerance
AU2003219383B2 (en) Oligonucleotide compositions and their use for the modulation of immune responses
EP2252329B1 (de) Beseitigung von immunreaktionen gegen virale vektoren
US9358277B2 (en) DNA vaccines and methods for the prevention of transplantation rejection
IL218269A (en) DNA vaccines encoded into heat-loss proteins
EP2146741A2 (de) Medikamente und verfahren zur behandlung von autoimmunerkrankungen und krebs
Dénes et al. Autoantigens plus interleukin-10 suppress diabetes autoimmunity
WO2009062502A1 (en) Method for generating tolerogenic dendritic cells employing decreased temperature
AU3601499A (en) Suppressive monocyte derived cells, process for their preparation and their uses in pharmaceutical compositions
EP1536826B1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
Dénes et al. Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses
Ferreira et al. Customized antigens for desensitizing allergic patients
US20070274949A1 (en) Cd25 Dna Vaccines for Treating and Preventing T-Cell Mediated Diseases
Biregani et al. Allergen specific immunotherapy with plasmid DNA encoding OVA-immunodominant T cell epitope fused to Tregitope in a murine model of allergy
CA3182111A1 (en) Immunogenic peptides with extended oxidoreductase motifs
Liu et al. Safely targeting autoimmunity in type 1 diabetes: the MonoPepT1De trial
EP1490086A2 (de) Verwendung eines organspezifischen selbsterregers zur behandlung einer nichtautoimmunkrankheit des entsprechenden organs
Verhagen et al. Advances in allergen-specific immunotherapy
Soyer et al. Immunologic Responses to Sublingual Allergen Immunotherapy
JP2024523476A (ja) 自己免疫に対する新規ｍＲＮＡワクチン
CA3220605A1 (en) Methods of treating or preventing autoimmune diseases
Dziadzio et al. New antiallergic drugs
Schwartz Immune-Based Cell Therapy for Acute and Chronic Neurodegeneratlve Disorders

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: ONEPHARM RESEARCH AND DEVELOPMENT GMBH, AT

Free format text: OLD OWNER(S): BIONETWORKS GMBH